Structure Determination of Tegoprazan(()-4-((5,7-difluorochroman-4-yl)oxy)-,,2-trimethyl-1-benzo[]imidazole-6-formamide) Polymorphs A and B by Laboratory X-Ray Powder Diffraction.

Tegoprazan is a potassium ion-competitive acid blocker (P-CAB) and a novel inhibitor of gastric acid secretion. The compound exists in two crystalline polymorphs, A and B, whose structures had not previously been reported. In this study, both polymorphs were analyzed by liquid- and solid-state NMR, revealing identical tautomeric states. Using this information, the crystal structures were determined from laboratory powder X-ray diffraction data by simulated annealing and Rietveld refinement. Both forms were found to crystallize in the monoclinic space group P2, with Z = 4 and two independent molecules in the asymmetric unit (Z' = 2). To assess the stability and reliability of the refined structures, we attempted geometry optimization and vibrational analysis using DFT-D methods. However, due to the high conformational complexity of Z' = 2 systems, these calculations failed to converge or produced imaginary frequencies. Instead, single-point energy calculations were performed on the refined models. The resulting relative energy differences, together with solubility data, van't Hoff enthalpies, and DSC profiles, consistently indicated that Polymorph A is more stable than Polymorph B. These results highlight the challenges of structure validation via DFT-D for complex molecular crystals and demonstrate the value of integrating experimental and computational approaches for polymorph characterization.